Prinaberel

Prinaberel (INN, USAN) (developmental code names ERB-041, WAY-202041) is a synthetic, nonsteroidal, and highly selective agonist of the ERβ subtype of the estrogen receptor.[1] It is used in scientific research to elucidate the role of the ERβ receptor.[2] Studies have indicated that selective ERβ agonists like prinaberel could be useful in the clinical treatment of a variety of medical conditions including inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis.[3] Accordingly, prinaberel either was or still is under investigation by Wyeth for the treatment of some of these conditions.[4]

Prinaberel
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
ECHA InfoCard100.222.969
Chemical and physical data
FormulaC15H10FNO3
Molar mass271.243 g/mol g·mol−1
3D model (JSmol)

See also

References
  1. Harris HA, Albert LM, Leathurby Y, et al. (October 2003). "Evaluation of an estrogen receptor-beta agonist in animal models of human disease". Endocrinology. 144 (10): 4241–9. doi:10.1210/en.2003-0550. PMID 14500559.
  2. Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA (May 2005). "Reflections on the discovery and significance of estrogen receptor beta". Endocrine Reviews. 26 (3): 465–78. doi:10.1210/er.2004-0027. PMID 15857973.
  3. Harris HA (2006). "Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic potential". Ernst Schering Foundation Symposium Proceedings (1): 149–61. PMID 17824176.
  4. "Prinaberel - Wyeth phase change II, USA (endometriosis)". R & D Focus Drug News. 2006-06-05. Archived from the original on 2016-03-07. Retrieved 2012-05-20.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.